Robert Goeltz II - Mar 8, 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Financial Officer
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Stock symbol: RCUS
Transactions as of: Mar 8, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/10/2022, 04:08 PM
Previous filing: Dec 20, 2021
Next filing: Dec 16, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Award	$0	+15.5K	+220.83%	$0.00	22.5K	Mar 8, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCUS	Stock Option (right to buy)	Award	$0	+62.5K		$0.00	62.5K	Mar 8, 2022	Common Stock	62.5K	$33.03	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.
F2	The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.